ISSN:
1573-739X
Keywords:
Biopharmaceutics
;
Carbamazepine
;
Clinical trials
;
Drug compounding
;
Pharmacokinetics
;
Tablets
;
Tablets, controlled release
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
Notes:
Abstract In an open, randomized, two-centre, cross-over study 20 patients formerly adjusted to a stable oral twice daily 200–600 mg carbamazepine dose, used ordinary tablets and divitabs (a new sustained-release formulation) for periods of three weeks, whereafter the serum level courses of carbamazepine and its metabolite carbamazepine-10,ll-epoxide were measured. The mean peak/mean trough carbamazepine-serum concentration ratio was slightly lower after the intake of divitabs in comparison to normal formulation: 1.14±0.447 versus 1.23±0.545 (mean ±SD). The mean trough levels of carbamazepine and its metabolite were 9% and 16% lower in the case of divitabs. In patients with peak/trough carbamazepine-serum level ratios of at least 1.30 after the intake of normal formulation, divitabs had a significant advantage.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF01972911
Permalink
